Nanoclays for the control of melanoma cell proliferation and cell viability
AssigneeKing Fahd University of Petroleum and Minerals
InventorsSahel N. ABDULJAUWAD, Habib-ur-Rehman AHMED
Life of this patent
Estimating the term…
Abstract
The invention pertains to a method for reducing proliferation or viability of melanoma cells by contacting the cells with nanoclay. It also involves pharmaceutical composition containing nanoclay for treatment of melanoma.
Claims20
1:
- A method for reducing melanoma cell growth viability, comprising:
- mixing the melanoma cells with a treatment composition consisting essentially of at least one nanoclay selected from the group consisting of a palygorskite and a montmorillonite as an active ingredient, to form a cell growth mixture, then
- incubating the cell growth mixture for from 3 to 5 days;
- wherein during the mixing the melanoma cells are present in a growth medium consisting essentially of water, amino acids and glucose,
- wherein the treatment composition contains the active ingredient in an amount of from 1 to 25 μg/ml,
- wherein after the incubating, the melanoma cell growth viability of the melanoma cells is reduced by at least 50% in comparison to the melanoma cell growth viability of a control growth mixture that is mixed with a control composition that is the same as the treatment composition but does not contain the active ingredient.
The method of claim 1, wherein said treatment composition contains the active ingredient in a concentration ranging from about 2 to 20 μg of the per cc or per gram of the treatment composition.
The method of claim 1, wherein said treatment composition contains the active ingredient in a concentration ranging from about 2 to 10 μg of the nanoclay per cc of per gram of the treatment composition.
4:
- The method of claim 1, wherein the at least one nanoclay consists essentially of palygorskite.
The method of claim 1, wherein the at least one nanoclay consists of palygorskite which has the formula (Mg,Al)2Si4O10(OH).4H2O.
6:
- The method of claim 1, wherein the at least one nanoclay consists essentially of a montmorillonite.
7:
- The method of claim 1, wherein the at least one nanoclay comprises a Na-rich montmorillonite having the formula (Na,Ca)0.33 (Al, Mg)2(Si4O10).
The method of claim 1, wherein the at least one nanoclay comprises a mixture of a palygorskite which has the formula (Mg,Al)2Si4O10(OH).4H2O and a Na-rich montmorillonite having the formula (Na, Ca)0.33(Al,Mg2(Si4O10).
9:
- A method for treating a subject having melanoma or another skin cancer comprising:
- administering a composition consisting essentially of at least one nanoclay selected from the group consisting of a palygorskite and a montmorillonite as an active ingredient to the subject, and, optionally, at least one inactive carrier or excipient.
The method of claim 9, wherein said composition contains the at least one nanoclay in a concentration ranging from about 1 to 200 μg of the nanoclay per cc or per gram of the composition.
The method of claim 9, wherein said composition contains the at least one nanoclay in a concentration ranging from about 2 to 20 μg of the nanoclay per cc of per gram of the composition.
12:
- The method of claim 9, wherein the at least one nanoclay consists essentially of palygorskite.
The method of claim 9, wherein the at least one nanoclay consists of palygorskite which has the formula (Mg, Al)2Si4O10(OH).4H2O.
14:
- The method of claim 9, wherein the at least one nanoclay consists essentially of a montmorillonite.
15:
- The method of claim 9, wherein the at least one nanoclay comprises a Na-rich montmorillonite having the formula (Na, Ca)0.33(Al, Mg)2(Si4O10).
The method of claim 9, wherein the at least one nanoclay comprises a mixture of a palygorskite which has the formula (Mg, Al)2Si4O10(OH).4H2O and a Na-rich montmorillonite having the formula (Na, Ca)0.33(Al, Mg)2(Si4O10).
The method of claim 9, wherein the at least one nanoclay is administered topically.
The method of claim 9, wherein at least one nanoclay is administered intradermally or subcutaneously.
The method of claim 1, wherein the at least one nanoclay is administered into or around a dermal site after removal of melanoma cells.
The method of claim 1, wherein the subject has been administered at least one other anti-cancer therapy.
Dependencies are inferred from the claim text.